目的:检测维吾尔族网膜脂肪组织KLF9及KLF15 m RNA表达水平,分析KLF9、KLF15与炎症信号通路关键因子的相关性。方法:选取维吾尔族个体NC组50例、OB组45例,检测一般资料和生化指标。采集网膜脂肪组织,RT-PCR法检测KLF9、KLF15及NF-κB炎...目的:检测维吾尔族网膜脂肪组织KLF9及KLF15 m RNA表达水平,分析KLF9、KLF15与炎症信号通路关键因子的相关性。方法:选取维吾尔族个体NC组50例、OB组45例,检测一般资料和生化指标。采集网膜脂肪组织,RT-PCR法检测KLF9、KLF15及NF-κB炎症信号通路关键因子m RNA表达水平。结果:OB组BMI、WC、HC、WHR、TG和LDL显著高于NC组,差异有统计学意义(P<0.05)。维吾尔族网膜脂肪组织中,OB组NF-κB、TNF-α和IL-6 m RNA表达水平显著高于NC组(P<0.05),NF-κB m RNA表达与体重和TG显著正相关(P<0.05),TNF-αm RNA表达与TG和TC显著正相关(P<0.05),IL-6 m RNA表达与HC、TG和LDL显著正相关(P<0.05);OB组网膜脂肪组织KLF15 m RNA表达水平显著低于NC组(P<0.05),与BMI、WC、WHR显著负相关(P<0.05),与HDL正相关,与TG负相关。KLF9 m RNA表达水平高于NC组,与NF-κB显著正相关(P<0.01),与IL-6正相关。结论:KLF15可能通过调控脂代谢发挥抗炎作用;肥胖状态下脂代谢紊乱可能间接上调KLF9的表达,而KLF9作为转录激活因子可能通过调控下游炎症因子的转录活性,从而促进炎症因子的表达和释放。展开更多
目的观察益气化瘀化痰法制剂对四氯化碳(CCL_4)所致肝纤维化大鼠模型的治疗作用及其可能机理。方法 105只雄性SD大鼠,随机选取10只为空白对照组,其余大鼠采用腹腔注射40%CCL4玉米油溶液联合高脂低蛋白饮食建立肝纤维化大鼠模型,成模后...目的观察益气化瘀化痰法制剂对四氯化碳(CCL_4)所致肝纤维化大鼠模型的治疗作用及其可能机理。方法 105只雄性SD大鼠,随机选取10只为空白对照组,其余大鼠采用腹腔注射40%CCL4玉米油溶液联合高脂低蛋白饮食建立肝纤维化大鼠模型,成模后随机分为模型组(10只)、秋水仙碱组、益气组、化瘀组、化痰组及益气化瘀化痰合剂组(各9只),分别给予相应药物制剂灌胃治疗,模型组及空白对照组以等量生理盐水灌胃,连续用药12周后处死大鼠。苏木素-伊红(HE)、马松(Masson)、天狼猩红(Sirius Red)染色观察肝组织形态学变化,RT-q PCR法检测肝组织KLF15、核因子κB(NF-κB)、白介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)、Ⅰ型胶原(Col-Ⅰ)、纤维连接蛋白(FN m RNA)表达水平,Western Blot检测肝组织NF-κB、IL-1β蛋白表达水平。结果与空白对照组比较,模型组大鼠肝组织大量胶原纤维沉积,纤维化明显;NF-κB、IL-1β、TNF-α、Col-Ⅰ、FN m RNA表达显著上调(P<0.01),KLF15 m RNA表达显著下调(P<0.01);NF-κB、IL-1β蛋白表达显著上调(P<0.05)。与模型组相比,各药物干预组肝纤维化程度减轻,NF-κB、IL-1β、TNF-α、Col-Ⅰ、FN m RNA表达下调(P<0.05),KLF15 m RNA表达上调(P<0.05),NF-κB、IL-1β蛋白表达显著下调(P<0.05),其中益气化瘀化痰合剂组各项指标改善最明显(P<0.05)。结论益气、化瘀、化痰法和秋水仙碱均可以降低肝组织内纤维化程度,改善部分纤维化指标,其作用机制可能与上调肝组织KLF15表达,抑制NF-κB等炎症相关因子的表达有关。其中益气化瘀化痰法合剂优于单法治疗和秋水仙碱治疗。展开更多
Background:Excessive abdominal fat deposition in commercial broilers presents an obstacle to profitable meat quality,feed utilization,and reproduction.Abdominal fat deposition depends on the proliferation of preadipoc...Background:Excessive abdominal fat deposition in commercial broilers presents an obstacle to profitable meat quality,feed utilization,and reproduction.Abdominal fat deposition depends on the proliferation of preadipocytes and their maturation into adipocytes,which involves a cascade of regulatory molecules.Accumulating evidence has shown that microRNAs(miRNAs)serve as post-transcriptional regulators of adipogenic differentiation in mammals.However,the miRNA-mediated molecular mechanisms underlying abdominal fat deposition in chickens are still poorly understood.This study aimed to investigate the biological functions and regulatory mechanism of miRNAs in chicken abdominal adipogenesis.Results:We established a chicken model of abdominal adipocyte differentiation and analyzed miRNA and mRNA expression in abdominal adipocytes at different stages of differentiation(0,12,48,72,and 120 h).A total of 217 differentially expressed miRNAs(DE-miRNAs)and 3520 differentially expressed genes were identified.Target prediction of DE-miRNAs and functional enrichment analysis revealed that the differentially expressed targets were significantly enriched in lipid metabolism-related signaling pathways,including the PPAR signaling and MAPK signaling pathways.A candidate miRNA,gga-miR-106-5p,exhibited decreased expression during the proliferation and differentiation of abdominal preadipocytes and was downregulated in the abdominal adipose tissues of fat chickens compared to that of lean chickens.gga-miR-106-5p was found to inhibit the proliferation and adipogenic differentiation of chicken abdominal preadipocytes.A dual-luciferase reporter assay suggested that the KLF15 gene,which encodes a transcriptional factor,is a direct target of gga-miR-106-5p.gga-miR-106-5p suppressed the posttranscriptional activity of KLF15,which is an activator of abdominal preadipocyte proliferation and differentiation,as determined with gain-and loss-of-function experiments.Conclusions:gga-miR-106-5p functions as an inhibitor of abdominal adipogenesis by targeting the KLF15 gene in chickens.These findings not only improve our understanding of the specific functions of miRNAs in avian adipogenesis but also provide potential targets for the genetic improvement of excessive abdominal fat deposition in poultry.展开更多
Renal unilateral ischemia-reperfusion injury(UIRI)constitutes a significant global health challenge,with poor recovery leading to chronic kidney disease and subsequent renal fibrosis.Extracellular vesicles(EVs)present...Renal unilateral ischemia-reperfusion injury(UIRI)constitutes a significant global health challenge,with poor recovery leading to chronic kidney disease and subsequent renal fibrosis.Extracellular vesicles(EVs)present substantial potential benefits for renal diseases.However,the limited yield and efficacy of EVs produced through traditional methodologies(2D-EVs)severely restrict their widespread application.Moreover,the efficient and effective strategies for using EVs in UIRI treatment and their mechanisms remain largely unexplored.In this study,we propose an innovative approach by integrating bioprinted mesenchymal stem cell microfiber extracellular vesicles production technology(3D-EVs)with a tail vein injection method,introducing a novel treatment strategy for UIRI.Our comparison of the biological functions of 2D-EVs and 3D-EVs,both in vitro and in vivo,reveals that 3D-EVs significantly outperform 2D-EVs.Specifically,in vitro,3D-EVs demonstrate a superior capacity to enhance the proliferation and migration of NRK-52E cells and mitigate hypoxia/reoxygenation(H/R)-induced injuries by reducing epithelial-mesenchymal transformation,extracellular matrix deposition,and ferroptosis.In vivo,3D-EVs exhibit enhanced therapeutic effects,as evidenced by improved renal function and decreased collagen deposition in UIRI mouse kidneys.We further elucidate the mechanism by which 3D-EVs derived from KLF15 ameliorate UIRI-induced tubular epithelial cells(TECs)ferroptosis through the modulation of SLC7A11 and GPX4 expression.Our findings suggest that bioprinted mesenchymal stem cells microfiberderived EVs significantly ameliorate renal UIRI,opening new avenues for effective and efficient EV-based therapies in UIRI treatment.展开更多
文摘目的:检测维吾尔族网膜脂肪组织KLF9及KLF15 m RNA表达水平,分析KLF9、KLF15与炎症信号通路关键因子的相关性。方法:选取维吾尔族个体NC组50例、OB组45例,检测一般资料和生化指标。采集网膜脂肪组织,RT-PCR法检测KLF9、KLF15及NF-κB炎症信号通路关键因子m RNA表达水平。结果:OB组BMI、WC、HC、WHR、TG和LDL显著高于NC组,差异有统计学意义(P<0.05)。维吾尔族网膜脂肪组织中,OB组NF-κB、TNF-α和IL-6 m RNA表达水平显著高于NC组(P<0.05),NF-κB m RNA表达与体重和TG显著正相关(P<0.05),TNF-αm RNA表达与TG和TC显著正相关(P<0.05),IL-6 m RNA表达与HC、TG和LDL显著正相关(P<0.05);OB组网膜脂肪组织KLF15 m RNA表达水平显著低于NC组(P<0.05),与BMI、WC、WHR显著负相关(P<0.05),与HDL正相关,与TG负相关。KLF9 m RNA表达水平高于NC组,与NF-κB显著正相关(P<0.01),与IL-6正相关。结论:KLF15可能通过调控脂代谢发挥抗炎作用;肥胖状态下脂代谢紊乱可能间接上调KLF9的表达,而KLF9作为转录激活因子可能通过调控下游炎症因子的转录活性,从而促进炎症因子的表达和释放。
文摘目的观察益气化瘀化痰法制剂对四氯化碳(CCL_4)所致肝纤维化大鼠模型的治疗作用及其可能机理。方法 105只雄性SD大鼠,随机选取10只为空白对照组,其余大鼠采用腹腔注射40%CCL4玉米油溶液联合高脂低蛋白饮食建立肝纤维化大鼠模型,成模后随机分为模型组(10只)、秋水仙碱组、益气组、化瘀组、化痰组及益气化瘀化痰合剂组(各9只),分别给予相应药物制剂灌胃治疗,模型组及空白对照组以等量生理盐水灌胃,连续用药12周后处死大鼠。苏木素-伊红(HE)、马松(Masson)、天狼猩红(Sirius Red)染色观察肝组织形态学变化,RT-q PCR法检测肝组织KLF15、核因子κB(NF-κB)、白介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)、Ⅰ型胶原(Col-Ⅰ)、纤维连接蛋白(FN m RNA)表达水平,Western Blot检测肝组织NF-κB、IL-1β蛋白表达水平。结果与空白对照组比较,模型组大鼠肝组织大量胶原纤维沉积,纤维化明显;NF-κB、IL-1β、TNF-α、Col-Ⅰ、FN m RNA表达显著上调(P<0.01),KLF15 m RNA表达显著下调(P<0.01);NF-κB、IL-1β蛋白表达显著上调(P<0.05)。与模型组相比,各药物干预组肝纤维化程度减轻,NF-κB、IL-1β、TNF-α、Col-Ⅰ、FN m RNA表达下调(P<0.05),KLF15 m RNA表达上调(P<0.05),NF-κB、IL-1β蛋白表达显著下调(P<0.05),其中益气化瘀化痰合剂组各项指标改善最明显(P<0.05)。结论益气、化瘀、化痰法和秋水仙碱均可以降低肝组织内纤维化程度,改善部分纤维化指标,其作用机制可能与上调肝组织KLF15表达,抑制NF-κB等炎症相关因子的表达有关。其中益气化瘀化痰法合剂优于单法治疗和秋水仙碱治疗。
基金supported by the National Key Research and Development Program of China(2021YFD1200803)Sanya Yazhou Bay Science and Technology City Administration(SYND-2022-28)China Agriculture Research System of MOF and MARA(CARS-40).
文摘Background:Excessive abdominal fat deposition in commercial broilers presents an obstacle to profitable meat quality,feed utilization,and reproduction.Abdominal fat deposition depends on the proliferation of preadipocytes and their maturation into adipocytes,which involves a cascade of regulatory molecules.Accumulating evidence has shown that microRNAs(miRNAs)serve as post-transcriptional regulators of adipogenic differentiation in mammals.However,the miRNA-mediated molecular mechanisms underlying abdominal fat deposition in chickens are still poorly understood.This study aimed to investigate the biological functions and regulatory mechanism of miRNAs in chicken abdominal adipogenesis.Results:We established a chicken model of abdominal adipocyte differentiation and analyzed miRNA and mRNA expression in abdominal adipocytes at different stages of differentiation(0,12,48,72,and 120 h).A total of 217 differentially expressed miRNAs(DE-miRNAs)and 3520 differentially expressed genes were identified.Target prediction of DE-miRNAs and functional enrichment analysis revealed that the differentially expressed targets were significantly enriched in lipid metabolism-related signaling pathways,including the PPAR signaling and MAPK signaling pathways.A candidate miRNA,gga-miR-106-5p,exhibited decreased expression during the proliferation and differentiation of abdominal preadipocytes and was downregulated in the abdominal adipose tissues of fat chickens compared to that of lean chickens.gga-miR-106-5p was found to inhibit the proliferation and adipogenic differentiation of chicken abdominal preadipocytes.A dual-luciferase reporter assay suggested that the KLF15 gene,which encodes a transcriptional factor,is a direct target of gga-miR-106-5p.gga-miR-106-5p suppressed the posttranscriptional activity of KLF15,which is an activator of abdominal preadipocyte proliferation and differentiation,as determined with gain-and loss-of-function experiments.Conclusions:gga-miR-106-5p functions as an inhibitor of abdominal adipogenesis by targeting the KLF15 gene in chickens.These findings not only improve our understanding of the specific functions of miRNAs in avian adipogenesis but also provide potential targets for the genetic improvement of excessive abdominal fat deposition in poultry.
基金supported by the Natural Science Foundation of China(Grant No.52075285)the Natural Science Foundation of Guang Dong Province(2019A1515010386,2024A1515010266).
文摘Renal unilateral ischemia-reperfusion injury(UIRI)constitutes a significant global health challenge,with poor recovery leading to chronic kidney disease and subsequent renal fibrosis.Extracellular vesicles(EVs)present substantial potential benefits for renal diseases.However,the limited yield and efficacy of EVs produced through traditional methodologies(2D-EVs)severely restrict their widespread application.Moreover,the efficient and effective strategies for using EVs in UIRI treatment and their mechanisms remain largely unexplored.In this study,we propose an innovative approach by integrating bioprinted mesenchymal stem cell microfiber extracellular vesicles production technology(3D-EVs)with a tail vein injection method,introducing a novel treatment strategy for UIRI.Our comparison of the biological functions of 2D-EVs and 3D-EVs,both in vitro and in vivo,reveals that 3D-EVs significantly outperform 2D-EVs.Specifically,in vitro,3D-EVs demonstrate a superior capacity to enhance the proliferation and migration of NRK-52E cells and mitigate hypoxia/reoxygenation(H/R)-induced injuries by reducing epithelial-mesenchymal transformation,extracellular matrix deposition,and ferroptosis.In vivo,3D-EVs exhibit enhanced therapeutic effects,as evidenced by improved renal function and decreased collagen deposition in UIRI mouse kidneys.We further elucidate the mechanism by which 3D-EVs derived from KLF15 ameliorate UIRI-induced tubular epithelial cells(TECs)ferroptosis through the modulation of SLC7A11 and GPX4 expression.Our findings suggest that bioprinted mesenchymal stem cells microfiberderived EVs significantly ameliorate renal UIRI,opening new avenues for effective and efficient EV-based therapies in UIRI treatment.
